| The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111 … M Bond, G Rogers, J Peters, R Anderson, M Hoyle, A Miners, T Moxham, ... Health technology assessment (Winchester, England) 16 (21), 1, 2012 | 377 | 2012 |
| A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. M Stevenson, ML Jones, E De Nigris, N Brewer, S Davis, J Oakley Health technology assessment (Winchester, England) 9 (22), 1-160, 2005 | 350 | 2005 |
| Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. JA Kanis, M Stevenson, EV McCloskey, S Davis, M Lloyd-Jones Health technology assessment (Winchester, England) 11 (7), iii-iv, ix, 2007 | 210 | 2007 |
| A systematic review and economic evaluation of exercise referral schemes in primary care: a short report F Campbell, M Holmes, E Everson-Hock, S Davis, HB Woods, N Anokye, ... Health technology assessment 19 (60), 2015 | 187 | 2015 |
| Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. S Ward, E Simpson, S Davis, D Hind, A Rees, A Wilkinson Health technology assessment (Winchester, England) 11 (40), 1-144, 2007 | 134 | 2007 |
| Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model C Hyde, J Peters, M Bond, G Rogers, M Hoyle, R Anderson, M Jeffreys, ... Age and ageing 42 (1), 14-20, 2013 | 130 | 2013 |
| The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. M Stevenson, S Davis, M Lloyd-Jones, C Beverley Health technology assessment (Winchester, England) 11 (4), 1-134, 2007 | 93 | 2007 |
| Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers O Ciani, S Davis, P Tappenden, R Garside, K Stein, A Cantrell, ED Saad, ... International journal of technology assessment in health care 30 (3), 312-324, 2014 | 89 | 2014 |
| Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis J Sanderson, M Martyn-St James, J Stevens, E Goka, R Wong, ... Bone 89, 52-58, 2016 | 81 | 2016 |
| A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. S Davis, MS James, J Sanderson, J Stevens, E Goka, A Rawdin, S Sadler, ... NIHR Health Technology Assessment Programme, 2016 | 81 | 2016 |
| NICE DSU Technical support document 15: Cost-effectiveness modelling using patient-level simulation S Davis, M Stevenson, P Tappenden, A Wailoo Rep BY Decis Support UNIT, 2014 | 70 | 2014 |
| Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis EL Simpson, M Martyn-St James, J Hamilton, R Wong, N Gittoes, P Selby, ... Bone 130, 115081, 2020 | 57 | 2020 |
| Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. S Davis, E Simpson, J Hamilton, M Martyn-St James, A Rawdin, R Wong, ... Health technology assessment (Winchester, England) 24 (29), 1, 2020 | 51 | 2020 |
| Implantable loop recorders are cost-effective when used to investigate transient loss of consciousness which is either suspected to be arrhythmic or remains unexplained S Davis, M Westby, D Pitcher, S Petkar Europace 14 (3), 402-409, 2012 | 47 | 2012 |
| The hospitalisation costs and out-patient costs of fragility fractures MD Stevenson, SE Davis, JA Kanis Women's Health Medicine 3 (4), 149-151, 2006 | 47 | 2006 |
| Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. J Leaviss, S Davis, S Ren, J Hamilton, A Scope, A Booth, A Sutton, ... Health technology assessment (Winchester, England) 24 (46), 1, 2020 | 44 | 2020 |
| The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease A Brennan, R Akehurst, S Davis, H Sakai, V Abbott Value in health 10 (1), 32-41, 2007 | 42 | 2007 |
| Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration N Bansback, S Davis, J Brazier Eye 21 (12), 1455-1463, 2006 | 36 | 2006 |
| Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results B Pennington, S Davis Value in health 17 (8), 762-771, 2014 | 35 | 2014 |
| A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration J Karnon, C Czoski-Murray, K Smith, C Brand, U Chakravarthy, S Davis, ... HEALTH TECHNOLOGY ASSESSMENT-SOUTHAMPTON- 12 (27), 2008 | 35 | 2008 |
Gabriel RogersUniversity of Manchester在 manchester.ac.uk 的电子邮件经过验证
